CN1668721B - 含有糖蛋白ⅵ结构域的免疫粘附素 - Google Patents

含有糖蛋白ⅵ结构域的免疫粘附素 Download PDF

Info

Publication number
CN1668721B
CN1668721B CN038172798A CN03817279A CN1668721B CN 1668721 B CN1668721 B CN 1668721B CN 038172798 A CN038172798 A CN 038172798A CN 03817279 A CN03817279 A CN 03817279A CN 1668721 B CN1668721 B CN 1668721B
Authority
CN
China
Prior art keywords
gpvi
thrombocyte
fusion protein
platelet
collagen protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN038172798A
Other languages
English (en)
Chinese (zh)
Other versions
CN1668721A (zh
Inventor
S·玛斯彼尔格
M·伽瓦兹
A·布尔特曼
G·曼驰
M·安格尔
M·佩鲁索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ava's Asset Management Ltd
Corimmun GmbH
Original Assignee
Trigen GmbH
Procorde GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trigen GmbH, Procorde GmbH filed Critical Trigen GmbH
Publication of CN1668721A publication Critical patent/CN1668721A/zh
Application granted granted Critical
Publication of CN1668721B publication Critical patent/CN1668721B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
CN038172798A 2002-06-07 2003-06-05 含有糖蛋白ⅵ结构域的免疫粘附素 Expired - Lifetime CN1668721B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02012742.9 2002-06-07
EP02012742A EP1369128A1 (en) 2002-06-07 2002-06-07 Inhibitors of glycoprotein VI and their therapeutic use
PCT/EP2003/005929 WO2003104282A2 (en) 2002-06-07 2003-06-05 Immunoadhesin comprising a glycoprotein vi domain

Publications (2)

Publication Number Publication Date
CN1668721A CN1668721A (zh) 2005-09-14
CN1668721B true CN1668721B (zh) 2012-11-14

Family

ID=29433140

Family Applications (1)

Application Number Title Priority Date Filing Date
CN038172798A Expired - Lifetime CN1668721B (zh) 2002-06-07 2003-06-05 含有糖蛋白ⅵ结构域的免疫粘附素

Country Status (13)

Country Link
US (1) US7514543B2 (cg-RX-API-DMAC7.html)
EP (4) EP1369128A1 (cg-RX-API-DMAC7.html)
JP (1) JP4722480B2 (cg-RX-API-DMAC7.html)
CN (1) CN1668721B (cg-RX-API-DMAC7.html)
AT (1) ATE346095T1 (cg-RX-API-DMAC7.html)
AU (2) AU2003236704B2 (cg-RX-API-DMAC7.html)
CA (1) CA2488630C (cg-RX-API-DMAC7.html)
DE (1) DE60309865T2 (cg-RX-API-DMAC7.html)
DK (1) DK1860118T3 (cg-RX-API-DMAC7.html)
ES (2) ES2276078T3 (cg-RX-API-DMAC7.html)
SI (1) SI1511770T1 (cg-RX-API-DMAC7.html)
WO (2) WO2003103662A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200409776B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
GB0511590D0 (en) * 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
WO2006061650A2 (en) * 2004-12-10 2006-06-15 Trigen Gmbh Methods, products and uses involving platelets and/or the vasculature
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
RU2407752C2 (ru) 2004-04-29 2010-12-27 Оцука Фармасьютикал Ко., Лтд. Антитела к гликопротеину vi и способы продуцирования и использования этих антител
US7645592B2 (en) 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
ES2381557T3 (es) 2004-08-03 2012-05-29 Innate Pharma Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
FR2884831B1 (fr) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
JP5224707B2 (ja) * 2005-04-28 2013-07-03 持田製薬株式会社 抗血小板膜糖蛋白質viモノクローナル抗体
CA2606450A1 (en) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
KR20080078675A (ko) * 2005-12-22 2008-08-27 시오노기 앤드 컴파니, 리미티드 급성 관상동맥 증후군의 예후 예측 방법
AU2008319336A1 (en) * 2007-10-31 2009-05-07 Otsuka Pharmaceutical Co., Ltd. Uses of a glycoprotein VI (GPVI) inhibitor
EP2352815B1 (en) * 2008-12-04 2016-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for producing platelets
DK2429574T3 (da) 2009-05-15 2015-06-22 Univ Health Network Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen
EP2397495A1 (en) * 2010-06-21 2011-12-21 Sanofi Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP2336188A1 (en) * 2009-12-18 2011-06-22 Sanofi-Aventis Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
JP5843783B2 (ja) * 2009-12-18 2016-01-13 サノフイ GPVIに対する新規アンタゴニスト抗体および該抗体のFabフラグメントならびにこれらの使用
EP2377888A1 (en) * 2010-04-07 2011-10-19 Corimmun GmbH Fusion protein
ME03550B (me) 2012-12-17 2020-07-20 Trillium Therapeutics Inc Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
CN104871005B (zh) * 2012-12-20 2016-07-06 藤森工业株式会社 血小板凝集能力的综合评价方法
EP3424957A1 (en) 2017-07-03 2019-01-09 advanceCOR GmbH Fusion protein
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技(上海)有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
WO2021158878A1 (en) * 2020-02-06 2021-08-12 Boehringer Ingelheim Animal Health USA Inc. Polypeptides useful for detecting anti-rhabdovirus antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000810A1 (en) * 1999-06-30 2001-01-04 Millennium Pharmaceuticals, Inc. Glycoprotein vi and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) * 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
ZA887365B (en) 1987-10-02 1990-05-30 Genentech Inc Adheson variants
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
US6406697B1 (en) * 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
GB9806806D0 (en) 1998-03-30 1998-05-27 Univ Cambridge Tech Peptides and uses thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9810999D0 (en) * 1998-05-21 1998-07-22 Goken Joop Materials and methods relating to the expression of genes
DK1177289T3 (da) 1999-05-07 2008-08-11 Sanofi Aventis Deutschland Rekombinant blodpladecollagenreceptor glycopotein VI og dets farmaceutiske anvendelse
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
PT2070939E (pt) 2001-05-25 2014-06-09 Univ Duke Moduladores de agentes farmacológicos
WO2003008454A2 (en) 2001-07-18 2003-01-30 Merck Patent Gmbh Glycoprotein vi fusion proteins
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
GB0130832D0 (en) 2001-12-22 2002-02-06 Univ Reading Modulation of the activity of the platelet endothelial cell adhesion molecule-1 (pecam-1)
GB0211750D0 (en) 2002-05-22 2002-07-03 Ouwehand Willem Abnormal blood conditions
EP1538165A1 (en) 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
US7531178B2 (en) * 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000810A1 (en) * 1999-06-30 2001-01-04 Millennium Pharmaceuticals, Inc. Glycoprotein vi and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
7,8.
NIESWANDT BERNHARD等.Glycoprotein VI but not alpha2betal integrin is essential forplatelet interaction with collagen.EMBO JOURNAL20 9.2001,20(9),全文.
NIESWANDT BERNHARD等.Glycoprotein VI but not alpha2betal integrin is essential forplatelet interaction with collagen.EMBO JOURNAL20 9.2001,20(9),全文. *

Also Published As

Publication number Publication date
AU2003250825A8 (en) 2003-12-22
ES2527717T3 (es) 2015-01-28
EP1860118A3 (en) 2008-07-30
EP1511770A2 (en) 2005-03-09
EP1511480A2 (en) 2005-03-09
ATE346095T1 (de) 2006-12-15
US7514543B2 (en) 2009-04-07
US20050079541A1 (en) 2005-04-14
EP1511770B1 (en) 2006-11-22
CN1668721A (zh) 2005-09-14
WO2003104282A3 (en) 2004-10-14
ZA200409776B (en) 2007-02-28
WO2003104282A8 (en) 2004-04-29
AU2003250825A1 (en) 2003-12-22
ES2276078T3 (es) 2007-06-16
WO2003103662A3 (en) 2004-11-04
DE60309865D1 (de) 2007-01-04
EP1369128A1 (en) 2003-12-10
WO2003104282A2 (en) 2003-12-18
EP1860118A2 (en) 2007-11-28
EP1860118B1 (en) 2014-12-31
DK1860118T3 (en) 2015-02-09
AU2003236704B2 (en) 2010-07-08
DE60309865T2 (de) 2007-10-18
AU2003236704A1 (en) 2003-12-22
JP2006512894A (ja) 2006-04-20
JP4722480B2 (ja) 2011-07-13
CA2488630A1 (en) 2003-12-18
CA2488630C (en) 2011-07-05
WO2003103662A2 (en) 2003-12-18
SI1511770T1 (sl) 2007-04-30

Similar Documents

Publication Publication Date Title
EP1511770B1 (en) Glycoprotein vi-fc fusion protein for the treatment of vascular diseases
US20240181050A1 (en) Agonist antibodies that bind human cd137 and uses thereof
US8119135B2 (en) Antibodies which bind to epitopes of glycoprotein VI
Massberg et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo
US12286483B2 (en) Method of treating cancer using CD137 antibodies and PD-1 antagonists
BR122022000386B1 (pt) Anticorpos que se ligam a cd39, composição farmacêutica e kit dos mesmos
CN101065138B (zh) 抑制hsp90与iap蛋白的蛋白-蛋白相互作用的化合物
CN1575338B (zh) 具有促细胞分裂活性的Bv8的核酸和多肽
US20090130021A1 (en) Methods, products and uses involving platelets and/or the vasculature
CN101883780A (zh) 人类cd154结合合成肽和其用途
US7531178B2 (en) Immunoadhesin comprising a glycoprotein VI domain
CN109265549A (zh) 一种具有中和活性的抗人Tim-1抗体
Tan et al. The assessment of platelet activation in antiplatelet drug development
EA046914B1 (ru) Антитела-агонисты, которые связывают cd137 человека, и варианты их применения
KR20160084177A (ko) 뮤턴트 루테리알에 특이적으로 결합하는 항체 및 이의 제조방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: KLIMN CO., LTD.

Free format text: FORMER OWNER: TERRYGEN CO., LTD.

Effective date: 20100525

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20100525

Address after: German Madingsilide

Applicant after: Trigen GmbH

Address before: German Madingsilide

Applicant before: Trigen Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: German Pla Neg

Patentee after: CORIMMUN GmbH

Address before: German Pla Neg

Patentee before: Ava's Asset Management Ltd.

CP01 Change in the name or title of a patent holder
TR01 Transfer of patent right

Effective date of registration: 20170522

Address after: German Pla Neg

Patentee after: Ava's Asset Management Ltd.

Address before: German Madingsilide

Patentee before: Trigen GmbH

TR01 Transfer of patent right
CX01 Expiry of patent term

Granted publication date: 20121114

CX01 Expiry of patent term